Fasudil and immunotherapy with hormone therapy for prostate cancer
Part of Cancer clinical trials.
This trial tests a new combination of drugs (Fasudil, a PD1 inhibitor, and hormone therapy) before prostate cancer surgery to see if it works better than standard treatment. It's for patients with early metastatic or locally advanced prostate cancer who haven't had any prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 85 years old.
- You must have prostate cancer confirmed by biopsy that doesn't have 'small cell' features.
- Your cancer must be either: locally advanced (stage cT3-4) or have up to 5 spots of spread in bones or lymph nodes (oligometastatic).
- You must be in good physical condition (ECOG 0-1, meaning you can do daily activities without help).
- You cannot have had any previous treatment for prostate cancer, including radiation, chemotherapy, or hormone therapy.
- You must agree to have your prostate surgically removed (radical prostatectomy) after the neoadjuvant therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of a chemotherapy drug (homoharringtonine) and hormone therapy (androgen deprivation) given before surgery to shrink prostate cancer that has spread a little or is advanced. The goal is to see if this approach can help control the cancer better before the prostate is removed.
This study tests whether adding a herbal supplement called Geranium Wilfordii to standard hormone therapy before surgery is safe and effective for treating prostate cancer that has spread a little or is locally advanced. The goal is to shrink the tumor and improve outcomes.
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
This trial tests a treatment that uses high-intensity focused ultrasound to target and destroy cancer cells in the prostate, combined with a newer hormone therapy. This approach may help control advanced prostate cancer and improve outcomes.
This trial tests a combination of drugs given before prostate removal surgery. The goal is to see if this treatment can shrink or slow high-risk prostate cancer.
Hear when a new Prostate CA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.